Merck KGaA Company Profile (NASDAQ:MKGAY)


Merck KGaA logoMerck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company operates through numerous subsidiaries, including Peer+ BV, AZ Electronic Materials (AZ), BioControl Systems Inc and Ormet Circuits Inc., a material supplier for the semiconductor industry.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MKGAY
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $39.80
  • 200 Day Moving Avg: $38.15
  • 52 Week Range: $32.53 - $42.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 5.57
  • P/E Growth: 0.00
  • Dividend Yield: 1.1%
  • Average Volume: 6,879 shs.

Frequently Asked Questions for Merck KGaA (NASDAQ:MKGAY)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the NASDAQ under the ticker symbol "MKGAY."

Who are some of Merck KGaA's key competitors?

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the folowing people:

  • Wolfgang Buechele, Chairman of the Supervisory Board
  • Stefan Oschmann Ph.D., Chairman of Executive Board and Chief Executive Officer
  • Michael Fletterich, Vice Chairman of the Supervisory Board, Employee Representative
  • Marcus Kuhnert, Member of the Executive Board, Chief Financial Officer
  • Udit Batra, CEO Life Science, Member of the Executive Board
  • Walter Heinrich Galinat, CEO Performance Materials, Member of the Executive Board
  • Belen Garijo, CEO Healthcare, Member of the Executive Board
  • Kai Beckmann, Chief Administrative Officer, Member of the Executive Board
  • Constantin Fest, Head of Investor Relations
  • Constantin Birnstiel, Head of Group Communications

How do I buy Merck KGaA stock?

Shares of Merck KGaA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck KGaA's stock price today?

One share of Merck KGaA stock can currently be purchased for approximately $38.36.

MarketBeat Community Rating for Merck KGaA (NASDAQ MKGAY)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  222
MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Merck KGaA (NASDAQ:MKGAY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating
Consensus Rating:Hold (Score: 1.50)
Consensus Price Target: N/A
Consensus Price Target History for Merck KGaA (NASDAQ:MKGAY)
Price Target History for Merck KGaA (NASDAQ:MKGAY)
Analysts' Ratings History for Merck KGaA (NASDAQ:MKGAY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Deutsche Bank AGReiterated RatingBuy -> HoldLowView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
10/14/2016Bank of America CorporationUpgradeNeutral -> BuyN/AView Rating Details
8/12/2016Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
8/10/2016Credit Suisse GroupUpgradeNeutral -> Outperform$73.00N/AView Rating Details
8/10/2016Jefferies Group LLCReiterated RatingHold$53.00 -> $57.00N/AView Rating Details
7/18/2016BMO Capital MarketsReiterated RatingMarket PerformN/AView Rating Details
5/25/2016DZ Bank AGReiterated RatingBuyN/AView Rating Details
5/19/2016J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
5/17/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
4/8/2016Nord/LBReiterated RatingBuyN/AView Rating Details
2/6/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$60.00 -> $56.00N/AView Rating Details
12/1/2015Barclays PLCUpgradeEqual Weight -> Overweight$64.00 -> $66.00N/AView Rating Details
11/17/2015ArgusReiterated RatingBuy$70.00 -> $65.00N/AView Rating Details
10/26/2015Societe GeneraleReiterated RatingNeutralN/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Merck KGaA (NASDAQ:MKGAY)
No earnings announcements for this company have been tracked by


Earnings Estimates for Merck KGaA (NASDAQ:MKGAY)
Current Year EPS Consensus Estimate: $6.99 EPS
Next Year EPS Consensus Estimate: $6.89 EPS


Dividend History for Merck KGaA (NASDAQ:MKGAY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merck KGaA (NASDAQ:MKGAY)
No insider trades for this company have been tracked by


Headline Trends for Merck KGaA (NASDAQ:MKGAY)
Latest Headlines for Merck KGaA (NASDAQ:MKGAY)
DateHeadline logoPfizer and Merck KGaA's Bavencio OK'd in Japan for rare skin cancer - September 27 at 9:36 AM logoMerck KGaA mulling sale of consumer health unit - September 5 at 9:31 PM logoBiocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO - August 31 at 2:08 AM logoMerck KGaA acquires chromatography membrane maker Natrix Separations - August 28 at 1:16 PM logoMerck KGaA Says NICE Issues Positive FAD Recommending Routine NHS Use Of Erbitux - August 9 at 12:14 AM logoMerck KgaA Q2 Profit Climbs, Maintains FY17 Earnings Forecast; Trims Sales View - August 3 at 5:26 AM logoMerck KGaA (NASDAQ:MKGAY) Given Average Recommendation of "Hold" by Brokerages - July 26 at 11:06 AM logoDeutsche Bank AG Downgrades Merck KGaA (MKGAY) to Hold - July 26 at 9:39 AM logoMerck KgaA' Cladribine Tablets Gets Positive CHMP Opinion For Treatment Of RMS - June 24 at 6:59 PM logoMerck KGaA Ventures Forms New Immuno-Oncology Company IOnctura - June 21 at 12:38 AM logoGerman Merck Doubles Down On Dual-Acting Cancer Agents - June 13 at 6:41 PM logoMerck Reveals Its Gastric Cancer Hand - June 6 at 7:16 PM logoMerck KgaA Q1 Profit Down, Sales Rise; Backs FY17 Organic Sales Growth View - May 19 at 11:06 AM logoMerck KgaA Q1 Profit Dips, Adj. EBITDA Rises; Backs FY17 Sales Growth View - May 18 at 8:32 AM logoMerck KGaA Plans Measures For Structural Development Of Its Business Sectors - May 17 at 6:30 PM logoTurmoil In Immuno-Oncology - May 15 at 10:25 AM logoKeytruda Gets Hot And Propels Merck: Analysis - May 11 at 7:04 PM logoPfizer : FDA Grants BAVENCIO Approval For Common Type Of Advanced Bladder Cancer - May 10 at 12:28 PM logoMerck KGaA : EC Grants Approval For New Pergoveris Pen For Fertility Treatment - May 10 at 12:28 PM logoMerck Raises Dividend - April 28 at 7:29 PM logoFresenius Shows Biotech How To Get The Deals Done - April 26 at 11:44 PM logoBeiGene, Another Beijing Venture In Cancer Therapy - March 25 at 6:13 PM logoMerck KGaA : FDA Approves First Treatment For Rare Form Of Skin Cancer - March 24 at 12:08 AM logoFDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer - March 23 at 7:06 PM logoPfizer And Merck Go For An Even Longer Throw Of The Javelin - March 11 at 12:52 AM logoMerck KgaA Q4 Profit More Than Doubles; Proposes Higher Dividend - March 9 at 8:44 AM logoMerck KgaA Q4 Profit Soars, Sees Stable Earnings In FY17; Stock Dips - March 9 at 8:44 AM logoFDA accepts EMD Serono's BLA for avelumab for urothelial carcinoma; action date August 27 - February 28 at 6:41 PM logoMerck KGaA teams up with Domain Therapeutics in immuno-oncology - January 23 at 10:10 AM logoAstra's Mystic Mystery And Other Surprises In Store - January 18 at 7:05 PM logoMerck KGaA And Palantir Launch New Healthcare Acceleration Partnership - January 13 at 5:07 AM logoVertex to collaborate with Germany's Merck in oncology - January 12 at 12:10 AM logoGerman Merck Unveils Its Secret Weapon - January 10 at 7:27 PM logoMerck Acquires BioControl to Strengthen Position in Food Safety Testing - January 4 at 7:23 PM logoMerck KGaA Acquires BioControl Systems - January 4 at 7:23 PM logoRoche Expands Distribution Agreement With Merck KgaA's Life Science Business - December 1 at 9:37 AM logoRoche expands distribution partnership with Merck KGaA - December 1 at 9:37 AM logoEvotec and Merck KGaA team up to discover new therapeutic targets - November 30 at 11:21 AM logo8:19 am Merck KGaA and Pfizer (PFE) announce that the FDA has accepted for Priority Review MKGAY's BLA for avelumab - November 29 at 2:51 PM logoFDA accepts avelumab BLA under Priority Review for rare type of skin cancer - November 29 at 2:51 PM logoQuintilesIMS forms collaboration with major drug firms to better understand real-world uses of cancer treatments - November 22 at 10:21 AM logoGermany's Merck Lifts Full Year Guidance After Sigma-Aldrich Boosts Sales - November 16 at 9:51 AM logoMerck KgaA Lifts FY16 Earnings View As Q3 Results Climb, Stock Up - November 15 at 9:52 AM logoTransgene Pins Hopes On Cancer Vaccine Combos - October 14 at 5:58 PM logoMerck KgaA To Meet 2018 Targets; Sees EUR 4 Bln Sales From New Products By 2022 - October 13 at 9:44 AM logoMerck KGaA Invests Over €50 Mln In Pharma Packaging Building In Darmstadt - September 21 at 10:17 AM



Merck KGaA (MKGAY) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.